© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
Daily Medication Pearl: Delafloxacin (Baxdela)
Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.
Medication Pearl of the Day: Delafloxacin (Baxdela)
Indication: Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.
Insight:
- Dosing: Administer delafloxacin for injection 300 mg by intravenous (IV) infusion over 60 minutes, every 12 hours, or a 450-mg delafloxacin tablet orally every 12 hours for 5 to 14 days total duration.
- Dosage forms: For Injection 300 mg of delafloxacin (equivalent to 433 mg delafloxacin meglumine) as a lyophilized powder in a single dose vial for reconstitution and further dilution before IV infusion.
- Adverse events: Most common adverse reactions (incidence ≥ 2%) are nausea, diarrhea, headache, transaminase elevations and vomiting.
- Mechanism of action: Delafloxacin is an antibacterial drug.
- Manufacturer: Melinta Therapeutics
Reference